Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men

Hyun Ah Kim, Young Il Seo, Yeong-Wook Song

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The aim of this study was to observe the effects of uric acid lowering therapy (UALT), febuxostat and allopurinol, on blood pressure (BP) and serum creatinine level. Post-hoc data were derived from a phase-III, randomised, double-blind, 4-week trial of male gouty patients that compared the safety and efficacy of febuxostat and allopurinol in adults with gout. The subjects were randomly assigned to one of five groups, 35-37 in each group (febuxostat: 40, 80, 120 mg/d; allopurinol: 300 mg/d; control group: placebo). Blood pressure and serum creatinine level were measured at baseline and at weeks 2 and 4. Diastolic BP and creatinine level had decreased significantly in the UALT groups compared to the control group at week 4. Diastolic BP had decreased significantly in the allopurinol group and serum creatinine level had decreased significantly in the febuxostat groups at week 4. After adjusting for confounding variables, serum uric acid changes were found to be significantly correlated with changes in serum creatinine level but were not associated with changes in systolic or diastolic BP. UALT in gouty subjects significantly decreased diastolic BP and serum creatinine level. Changes in uric acid were significantly correlated with those in serum creatinine level, suggesting the feasibility of renal function improvement through UALT in gouty men.

Original languageEnglish
Pages (from-to)1077-1081
Number of pages5
JournalJournal of Korean Medical Science
Volume29
Issue number8
DOIs
StatePublished - 1 Jan 2014

Fingerprint

Allopurinol
Creatinine
Blood Pressure
Uric Acid
Serum
Therapeutics
Febuxostat
Control Groups
Confounding Factors (Epidemiology)
Gout
Patient Safety
Group Psychotherapy
Placebos
Kidney

Keywords

  • Allopurinol
  • Blood pressure
  • Creatinine
  • Febuxostat
  • Gout
  • Hyperuricemia

Cite this

@article{09c08875bd5b44d79ffc908cdf08df17,
title = "Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men",
abstract = "The aim of this study was to observe the effects of uric acid lowering therapy (UALT), febuxostat and allopurinol, on blood pressure (BP) and serum creatinine level. Post-hoc data were derived from a phase-III, randomised, double-blind, 4-week trial of male gouty patients that compared the safety and efficacy of febuxostat and allopurinol in adults with gout. The subjects were randomly assigned to one of five groups, 35-37 in each group (febuxostat: 40, 80, 120 mg/d; allopurinol: 300 mg/d; control group: placebo). Blood pressure and serum creatinine level were measured at baseline and at weeks 2 and 4. Diastolic BP and creatinine level had decreased significantly in the UALT groups compared to the control group at week 4. Diastolic BP had decreased significantly in the allopurinol group and serum creatinine level had decreased significantly in the febuxostat groups at week 4. After adjusting for confounding variables, serum uric acid changes were found to be significantly correlated with changes in serum creatinine level but were not associated with changes in systolic or diastolic BP. UALT in gouty subjects significantly decreased diastolic BP and serum creatinine level. Changes in uric acid were significantly correlated with those in serum creatinine level, suggesting the feasibility of renal function improvement through UALT in gouty men.",
keywords = "Allopurinol, Blood pressure, Creatinine, Febuxostat, Gout, Hyperuricemia",
author = "Kim, {Hyun Ah} and Seo, {Young Il} and Yeong-Wook Song",
year = "2014",
month = "1",
day = "1",
doi = "10.3346/jkms.2014.29.8.1077",
language = "English",
volume = "29",
pages = "1077--1081",
journal = "Journal of Korean medical science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "8",

}

Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. / Kim, Hyun Ah; Seo, Young Il; Song, Yeong-Wook.

In: Journal of Korean Medical Science, Vol. 29, No. 8, 01.01.2014, p. 1077-1081.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men

AU - Kim, Hyun Ah

AU - Seo, Young Il

AU - Song, Yeong-Wook

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The aim of this study was to observe the effects of uric acid lowering therapy (UALT), febuxostat and allopurinol, on blood pressure (BP) and serum creatinine level. Post-hoc data were derived from a phase-III, randomised, double-blind, 4-week trial of male gouty patients that compared the safety and efficacy of febuxostat and allopurinol in adults with gout. The subjects were randomly assigned to one of five groups, 35-37 in each group (febuxostat: 40, 80, 120 mg/d; allopurinol: 300 mg/d; control group: placebo). Blood pressure and serum creatinine level were measured at baseline and at weeks 2 and 4. Diastolic BP and creatinine level had decreased significantly in the UALT groups compared to the control group at week 4. Diastolic BP had decreased significantly in the allopurinol group and serum creatinine level had decreased significantly in the febuxostat groups at week 4. After adjusting for confounding variables, serum uric acid changes were found to be significantly correlated with changes in serum creatinine level but were not associated with changes in systolic or diastolic BP. UALT in gouty subjects significantly decreased diastolic BP and serum creatinine level. Changes in uric acid were significantly correlated with those in serum creatinine level, suggesting the feasibility of renal function improvement through UALT in gouty men.

AB - The aim of this study was to observe the effects of uric acid lowering therapy (UALT), febuxostat and allopurinol, on blood pressure (BP) and serum creatinine level. Post-hoc data were derived from a phase-III, randomised, double-blind, 4-week trial of male gouty patients that compared the safety and efficacy of febuxostat and allopurinol in adults with gout. The subjects were randomly assigned to one of five groups, 35-37 in each group (febuxostat: 40, 80, 120 mg/d; allopurinol: 300 mg/d; control group: placebo). Blood pressure and serum creatinine level were measured at baseline and at weeks 2 and 4. Diastolic BP and creatinine level had decreased significantly in the UALT groups compared to the control group at week 4. Diastolic BP had decreased significantly in the allopurinol group and serum creatinine level had decreased significantly in the febuxostat groups at week 4. After adjusting for confounding variables, serum uric acid changes were found to be significantly correlated with changes in serum creatinine level but were not associated with changes in systolic or diastolic BP. UALT in gouty subjects significantly decreased diastolic BP and serum creatinine level. Changes in uric acid were significantly correlated with those in serum creatinine level, suggesting the feasibility of renal function improvement through UALT in gouty men.

KW - Allopurinol

KW - Blood pressure

KW - Creatinine

KW - Febuxostat

KW - Gout

KW - Hyperuricemia

UR - http://www.scopus.com/inward/record.url?scp=84929155497&partnerID=8YFLogxK

U2 - 10.3346/jkms.2014.29.8.1077

DO - 10.3346/jkms.2014.29.8.1077

M3 - Article

C2 - 25120316

AN - SCOPUS:84929155497

VL - 29

SP - 1077

EP - 1081

JO - Journal of Korean medical science

JF - Journal of Korean medical science

SN - 1011-8934

IS - 8

ER -